Taysha Gene Therapies Net Income
| TSHA Stock | USD 4.55 0.10 2.15% |
As of the 14th of February 2026, Taysha Gene has the Semi Deviation of 4.09, risk adjusted performance of 0.068, and Coefficient Of Variation of 1350.31. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Taysha Gene Therapies, as well as the relationship between them.
Taysha Gene Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 166.5429 | Revenue | Earnings Share (0.33) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -157.1 M | -149.2 M | |
| Net Loss | -80.4 M | -84.4 M | |
| Net Loss | -80.4 M | -84.4 M | |
| Net Loss | (0.32) | (0.34) | |
| Net Income Per E B T | 0.64 | 0.58 |
Taysha | Net Income | Build AI portfolio with Taysha Stock |
Analyzing Taysha Gene's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Taysha Gene's current valuation and future prospects.
Latest Taysha Gene's Net Income Growth Pattern
Below is the plot of the Net Income of Taysha Gene Therapies over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Taysha Gene Therapies financial statement analysis. It represents the amount of money remaining after all of Taysha Gene Therapies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Taysha Gene's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Taysha Gene's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (89.3 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Taysha Net Income Regression Statistics
| Arithmetic Mean | (44,723,871) | |
| Coefficient Of Variation | (136.78) | |
| Mean Deviation | 51,507,363 | |
| Median | (1,115,000) | |
| Standard Deviation | 61,174,848 | |
| Sample Variance | 3742.4T | |
| Range | 173.4M | |
| R-Value | (0.72) | |
| Mean Square Error | 1914.1T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (8,739,922) | |
| Total Sum of Squares | 59877.8T |
Taysha Net Income History
Other Fundumenentals of Taysha Gene Therapies
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Taysha Gene Net Income component correlations
Taysha Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Taysha Gene is extremely important. It helps to project a fair market value of Taysha Stock properly, considering its historical fundamentals such as Net Income. Since Taysha Gene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Taysha Gene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Taysha Gene's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Taysha Gene assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.33) | Revenue Per Share | Quarterly Revenue Growth 0.786 | Return On Assets | Return On Equity |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Taysha Gene's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Taysha Gene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Taysha Gene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Taysha Gene.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Taysha Gene on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Taysha Gene Therapies or generate 0.0% return on investment in Taysha Gene over 90 days. Taysha Gene is related to or competes with Dianthus Therapeutics, Sana Biotechnology, Oculis Holding, AnaptysBio, BridgeBio Oncology, Immatics, and Xencor. Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-ba... More
Taysha Gene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Taysha Gene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Taysha Gene Therapies upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.4 | |||
| Information Ratio | 0.0589 | |||
| Maximum Drawdown | 21.14 | |||
| Value At Risk | (6.94) | |||
| Potential Upside | 7.92 |
Taysha Gene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taysha Gene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Taysha Gene's standard deviation. In reality, there are many statistical measures that can use Taysha Gene historical prices to predict the future Taysha Gene's volatility.| Risk Adjusted Performance | 0.068 | |||
| Jensen Alpha | 0.2151 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0616 | |||
| Treynor Ratio | 0.1709 |
Taysha Gene February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.068 | |||
| Market Risk Adjusted Performance | 0.1809 | |||
| Mean Deviation | 3.57 | |||
| Semi Deviation | 4.09 | |||
| Downside Deviation | 4.4 | |||
| Coefficient Of Variation | 1350.31 | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.24 | |||
| Information Ratio | 0.0589 | |||
| Jensen Alpha | 0.2151 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.0616 | |||
| Treynor Ratio | 0.1709 | |||
| Maximum Drawdown | 21.14 | |||
| Value At Risk | (6.94) | |||
| Potential Upside | 7.92 | |||
| Downside Variance | 19.4 | |||
| Semi Variance | 16.7 | |||
| Expected Short fall | (3.79) | |||
| Skewness | 0.2935 | |||
| Kurtosis | 0.0749 |
Taysha Gene Therapies Backtested Returns
Taysha Gene appears to be moderately volatile, given 3 months investment horizon. Taysha Gene Therapies owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0582, which indicates the firm had a 0.0582 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Taysha Gene Therapies, which you can use to evaluate the volatility of the company. Please review Taysha Gene's Risk Adjusted Performance of 0.068, semi deviation of 4.09, and Coefficient Of Variation of 1350.31 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Taysha Gene holds a performance score of 4. The entity has a beta of 1.94, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Taysha Gene will likely underperform. Please check Taysha Gene's skewness, and the relationship between the downside variance and daily balance of power , to make a quick decision on whether Taysha Gene's existing price patterns will revert.
Auto-correlation | -0.79 |
Almost perfect reverse predictability
Taysha Gene Therapies has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Taysha Gene time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Taysha Gene Therapies price movement. The serial correlation of -0.79 indicates that around 79.0% of current Taysha Gene price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.79 | |
| Spearman Rank Test | -0.69 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Taysha Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Taysha Gene Therapies reported net income of (89.3 Million). This is 126.17% lower than that of the Biotechnology sector and 227.49% lower than that of the Health Care industry. The net income for all United States stocks is 115.64% higher than that of the company.
Taysha Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taysha Gene's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taysha Gene could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics of similar companies.Taysha Gene is currently under evaluation in net income category among its peers.
Taysha Gene Current Valuation Drivers
We derive many important indicators used in calculating different scores of Taysha Gene from analyzing Taysha Gene's financial statements. These drivers represent accounts that assess Taysha Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Taysha Gene's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 382.0M | 86.5M | 179.0M | 376.8M | 433.4M | 404.7M | |
| Enterprise Value | 296.0M | 58.5M | 96.2M | 301.0M | 346.1M | 308.7M |
Taysha Gene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Taysha Gene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Taysha Gene's managers, analysts, and investors.Environmental | Governance | Social |
Taysha Gene Institutional Holders
Institutional Holdings refers to the ownership stake in Taysha Gene that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Taysha Gene's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Taysha Gene's value.| Shares | Point72 Asset Management, L.p. | 2025-06-30 | 7.3 M | Deerfield Management Co | 2025-06-30 | 5.4 M | State Street Corp | 2025-06-30 | 5.1 M | Polar Capital Holdings Plc | 2025-06-30 | 5 M | Adage Capital Partners Gp Llc | 2025-06-30 | 4.8 M | The Toronto-dominion Bank | 2025-06-30 | 4.7 M | Tybourne Capital Management (hk) Ltd | 2025-06-30 | 4.1 M | Baker Bros Advisors Lp | 2025-06-30 | 4 M | Geode Capital Management, Llc | 2025-06-30 | 3.8 M | Rtw Investments, Llc | 2025-06-30 | 25 M | Ra Capital Management, Llc | 2025-06-30 | 23.6 M |
Taysha Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (16.19) % | ||||
| Current Valuation | 1.05 B | ||||
| Shares Outstanding | 273.92 M | ||||
| Shares Owned By Insiders | 11.13 % | ||||
| Shares Owned By Institutions | 98.31 % | ||||
| Number Of Shares Shorted | 55.69 M | ||||
| Price To Book | 5.84 X | ||||
| Price To Sales | 201.86 X | ||||
| Revenue | 8.33 M | ||||
| Gross Profit | 6.31 M | ||||
| EBITDA | (87.95 M) | ||||
| Net Income | (89.3 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 63.18 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.80 X | ||||
| Cash Flow From Operations | (81.22 M) | ||||
| Short Ratio | 20.39 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 73 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 1.27 B | ||||
| Total Asset | 160.36 M | ||||
| Retained Earnings | (602.3 M) | ||||
| Working Capital | 115.9 M | ||||
| Net Asset | 160.36 M |
About Taysha Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taysha Gene Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:Check out You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Taysha Gene assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.33) | Revenue Per Share | Quarterly Revenue Growth 0.786 | Return On Assets | Return On Equity |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Taysha Gene's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.